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Cushing’s disease, or pituitary ACTH dependent Cushing’s syndrome, is a rare disease responsible for increased
morbidity and mortality. Signs and symptoms of hypercortisolism are usually non specific: obesity, signs of protein
wasting, increased blood pressure, variable levels of hirsutism. Diagnosis is frequently difficult, and requires a strict
algorithm. First-line treatment is based on transsphenoidal surgery, which cures 80% of ACTH-secreting
microadenomas. The rate of remission is lower in macroadenomas. Other therapeutic modalities including
anticortisolic drugs, radiation techniques or bilateral adrenalectomy will thus be necessary to avoid long-term risks
(metabolic syndrome, osteoporosis, cardiovascular disease) of hypercortisolism. This review summarizes potential
pathophysiological mechanisms, diagnostic approaches, and therapies.Disease name and synonyms
Cushing’s disease, corticotroph adenoma, pituitary
dependent Cushing’s syndrome.
Chronic glucocorticoid excess, or Cushing’s syn-
drome, may be due to ACTH-dependent (80% cases) or
–independent (20% cases) causes (Table 1). The latter
are mainly due to benign (60%) or malignant (40%) ad-
renal tumors. ACTH overproduction may be of pituit-
ary origin (85% cases) or result from ectopic tumor
secretion (15% cases). The term Cushing’s disease is
specifically applied to ACTH-secreting pituitary tumors.
Cushing’s disease, first described by Harvey Cushing in
1932, represents the most frequent cause of Cushing’s
syndrome [1].
Cushing’s disease is defined by Adrenocorticotropin
hormone (ACTH) hypersecretion, induced by a cortico-
troph adenoma, and leading to cortisol hypersecretion
(associated with androgens hypersecretion).
Epidemiology
The incidence of Cushing’s syndrome is estimated to be
equal to 1–3 cases per million inhabitants per year,
whereas its prevalence is close to 40 cases per million
inhabitants. Of note, prevalence of hypercortisolism is
thought to be equal to 2-5% of patients with poorly con-
trolled diabetes and hypertension. Female preponder-
ance is generally assumed to be close to 3:1 [2].* Correspondence: Frederic.castinetti@ap-hm.fr; Thierry.brue@ap-hm.fr
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reproduction in any medium, provided the orCushing’s disease is an extremely rare condition in chil-
dren, with a peak in adults in the 3rd or 4th decade.
Cushing’s disease leads to death if untreated; it is re-
sponsible for increased morbidity and mortality, due to
cardiovascular complications, infections and psychiatric
disturbances [3,4].
Clinical and biological characteristics
Clinical characteristics
Hypercortisolic state may include several clinical signs [5,6]
– Obesity: obesity with centripetal fat deposition (face,
supraclavicular and dorso-cervical fat pads), facial
plethora, rounded face, buffalo-hump
– Signs of protein wasting: thin skin, abdominal purple
to red and wide cutaneous striae (abdomen, flanks,
breasts, hips, axillae), easy bruising, slow healing,
muscle wasting (lower limbs muscle atrophy)
– Bone wasting leading to osteoporosis (possibly
leading to fractures)
– High blood pressure
– Impaired immune defense mechanisms with
increased rate of infections
– Gonadal dysfunction and hyperandrogenism:
hirsutism (more frequently on the face), menstrual
irregularity (oligoamenorrhea, amenorrhea)
– Mild to severe psychic disturbances(anxiety,
depression, irritability. . .)
The most frequent sign is obesity: abnormal fat distri-
bution is considered as the most sensitive sign [7].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the most specific sign. Conjunction of both should
theoretically allow to distinguish between hypercortiso-
lism and simple obesity. However, the severity of hyper-
cortisolism can be highly variable, which frequently
makes the diagnosis difficult. Moreover, hypersecretion
profiles can be cyclical, leading to very modest pheno-
typic signs in some patients (subclinical Cushing’s syn-
drome) [8]. In most cases, diagnosis depends on a high
index of suspicion, rather than a florid clinical pheno-
type. Of note, none of the signs can allow to differentiate
Cushing’s disease from any other etiology of hypercorti-
solism, except in case of tumor related symptoms such
as headaches or visual field defect (in macroadenomas).
Biological characteristics
Non-specific biological signs may include hypokalemia
and impaired glucose tolerance or diabetes. Blood count
may show increased hemoglobin, increased neutrophils
and decreased lymphocytes or eosinophils.
Etiopathogenesis
Characteristics of corticotroph adenomas Cushing’s
disease is frequently due to monoclonal benign and slow
growing microadenomas (less than 10 mm) [9,10].
Plasma ACTH (and cortisol) classically lose their physio-
logic circadian periodicity. They are partially resistant to
physiologic stimuli (i.e., glucocorticoids), and do not
respond to the normal feedback negative loop. In
contrast, corticotroph adenomas are inappropriately
sensitive to CRH and AVP. Altered CRH secretion as
well as POMC qualitative changes in gene expression
were also reported to be involved in the pathogenesis of
Cushing’s disease. Cushing’s disease can be more
atypical: secretion profiles are sometimes cyclic, with
hypersecretion preceding a long period of normal secre-
tion [8,11]. Some corticotroph adenomas are called
“silent” as they are clinically and biologically comparableto non-secreting pituitary adenomas: diagnosis is made
by the pathologist [12]. Finally, rare cases of aggressive
pituitary adenomas or carcinomas have been reported
[13]. Whether hyperplasia of corticotroph cells is or not
a required initial step before the genesis of corticotroph
adenoma remains a matter of debate. The origin of the
disease, primary pituitary condition or secondary to an
abnormality in the hypothalamus (chronic stimulation
by CRH [14]), remains a matter of debate.
Genetic predisposition Cushing’s disease can be part of
Multiple Endocrine Neoplasia Type 1, due to mutations of
the menin gene. It is a rare syndrome, transmitted in an
autosomal dominant manner, which associates hyperpara-
thyroidism, endocrine tumors, and pituitary adenomas in
20-50% cases. Most of these are somatotroph or lacto-
troph, but corticotroph adenomas have been described in
5-10% of cases. AIP (Aryl hydrocarbon receptor Interacting
Protein) mutations have been reported in familial pituitary
adenomas: secretion profile is usually somatotroph or
lactotroph, whereas very rare cases of CD have also been
reported [15].
Potentially involved molecular mechanisms Triggering
signals leading to Cushing’s disease remain unclear. Onco-
genes do not appear to be involved, as somatic mutations
are usually not present in corticotroph adenomas cells.
Recent studies in mice identified a potential role of loss of
function of Brg1 (brahma-related gene 1) and HDAC2
(Histone Deacetylase 2) in the pathogenesis of Cushing’s
disease. Both proteins form a complex with the gluco-
corticoid receptor and the orphan nuclear receptor nu-
clear growth factor IB (NGFI-B) to repress POMC
secretion. Interestingly, about 50% of corticotroph aden-
omas do not express these proteins anymore. The loss of
Brg1 could lead to overexpression of cyclin E, leading to
increased cell proliferation and sporadic hyperplasia or
tumors. Interestingly, tumors with a loss of nuclear
localization of Brg1 seem to be more responsive to
anticortisolic drugs in vitro compared to the ones with a
complete loss of Brg1 oncogene [16,17].
Transcription factors involved in progenitors prolifera-
tion and differentiation during pituitary embryogenesis
could also be involved in pituitary tumorigenesis. TPIT
deficiency is known to result in congenital isolated corti-
cotroph deficiency. Patients with other pituitary tran-
scription factors mutations (PROP1, LHX3, LHX4,
HESX1) usually present combined pituitary hormone de-
ficiencies including inconstant corticotroph deficiency.
As some of these factors are still expressed at adult age,
and their role is not precisely known, it could be tempt-
ing to speculate on potential roles of an overexpression
of these proteins in pituitary adenomas ontogenesis.
However, to our knowledge, no mutation of any
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presenting with corticotroph adenomas [18,19].
Diagnosis
Diagnosis of Cushing’s disease is difficult [20]. Clinical
signs and symptoms are often non-specific; no single
biological test combines optimal sensitivity and specifi-
city for the diagnosis of hypercortisolism and for the de-
termination of its etiology [21]. Moreover, pituitary and
adrenal imaging can sometimes be confusing.
Several steps are needed to first confirm the diagnosis
of hypercortisolism and then determine its origin: the
first will be to confirm the lack of exposure to exogen-
ous glucocorticoids that induces the same clinical char-
acteristics as Cushing’s syndrome and makes
hypercortisolism screening unavailable [22]. In normal
subjects, cortisol levels reach a peak at early morning
and a nadir< 50 nmol/l around midnight. Patients with
Cushing’s syndrome lose this circadian rhythm. As a
consequence, early morning ACTH and cortisol values
are of poor diagnostic value in the screening methods of
hypercortisolism. In contrast a midnight cortisol
value> 200 nmol/l is strongly suggestive of Cushing’s
syndrome [23]. Evaluation of the circardian rhythm of
cortisol is however not recommended as a first line
screening method for hypercortisolism.
We will not detail precisely all methods and tests pro-
posed to confirm a diagnosis of hypercortisolism (or
Cushing’s syndrome, CS): these criteria have been widely
described in recent consensus conferences[6,24]. First
line screening methods should include either
– 24-hour urinary free cortisol, repeated at least twice;
values should be above 220–330 nmol/24 h
depending on the assays, in Cushing’s syndrome,
keeping in mind that normal values can be seen in
8-15% of patients with Cushing’s syndrome [25]
– cortisol response to 1 mg-overnight dexamethasone
suppression test: cortisol value< 50 nmol/l (< 2 μg/dl)
excludes Cushing’s syndrome with high sensitivity
(95%) but low specificity [26].
– cortisol response to low dose dexamethasone
suppression test (0.5 mg dexamethasone every 6
hours during 48 hours): cortisol value< 50 nmol/l
(< 2 μg/dl) excludes Cushing’s syndrome with a
sensitivity and specificity close to 100% [27].
– or late night salivary cortisol [25,28,29] : a cortisol
value> 2 ng/ml (5.5 nmol/l) has a 100% sensitivity
and 96% specificity for Cushing’s syndrome [30].
Pseudo Cushing’s syndrome is defined by the presence
of partial clinical signs of hypercortisolism. It can be
induced by chronic alcohol consumption, depression
and obesity. Diagnosis between Cushing’s syndrome andpseudo Cushing’s syndrome might be difficult despite
the use of previously described screening methods [6].
CRH injection coupled with dexamethasone suppression
test, is in favor of Cushing’s syndrome with 90% sensitiv-
ity and 84% specificity in the presence of peak
cortisol> 580 nmol/l and ACTH> 50 pg/ml [31].
Steps for positive diagnosis of Cushing’s syndrome are
summarized in Figure 1.
When the presence of CS is confirmed, diagnosis ap-
proach will determine if the secretion is ACTH-dependent
or not. Early morning undetectable ACTH levels (< 10 pg/
ml) will lead to a diagnosis of ACTH independent hyper-
cortisolism (autonomous adrenal hypersecretion), whereas
inappropriately normal or increased levels (> 10 pg/ml)
will be in favor of an ACTH-dependent hypercortisolism.
ACTH dependent CS includes Cushing’s disease (CD)
and, more rarely, ectopic ACTH secretion (EAS) [32].
Distinction between both is difficult, and frequently
requires the use of several diagnostic methods [33]:
– high dose dexamethasone suppression test (8 mg/day
during 2 days): a decrease of more than 50% urinary
cortisol level is observed in 90% of patients with CD,
compared with less than 50% of those with EAS. Of
note, more than 90% suppression of urinary cortisol
has 100% specificity in the diagnosis of Cushing’s
disease [2].
– CRH test (100 μg intra-venously): more than 50%
ACTH and 20% cortisol increase is in favor of
Cushing’s disease. Sensitivity and specificity are close
to 90% [34].
– Desmopressin test (10 μg intravenously), ACTH and
cortisol increases similar to those observed with the
CRH test are in favor of CD with 70% sensitivity and
85% specificity [20,35]
Concordant responses to at least 2/3 of these tests
should lead to the diagnosis of Cushing’s disease, and
pituitary MRI. However, the sensitivity of MRI in CD is
hardly greater than 60-70% and specificity close to 85%,
as most corticotroph adenomas are microadenomas. In
one study, 10% of the general population presented MRI pi-
tuitary images of less than 5 mm that might be considered
as adenomas [36]. Cushing’s disease diagnosis is thus con-
firmed in the presence of an adenoma> 6 mm and con-
cordant responses to tests.
In the lack of an image suggesting a pituitary adenoma
on MRI despite dynamic tests in favor of CD, or in case
of discordant tests, bilateral intra-petrosal sinus sam-
pling (stimulated by CRH or desmopressin) should be
performed: it will give a definite answer to confirm the
etiology of ACTH dependent CS. The principle is to
measure a ratio defined by central ACTH/peripheral
ACTH. A central to peripheral plasma ACTH ratio
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Figure 1 Steps necessary to confirm the diagnosis of Cushing’s syndrome.
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of Cushing’s disease[37-40] .In case of ACTH dependent
hypercortisolism, if the initial etiologic workup is not in
favor of a pituitary origin, complementary morphologic
investigation including tomodensitometric whole body
examination should be performed. Some teams prefer to
perform systematically a thoraco–abdomino-pelvic scan
in each patient with ACTH dependent Cushing’s syn-
drome, whatever the status of tests and MRI. The limit
of this approach is identical to the one reported with pi-
tuitary MRI, as some patients might have bronchial inci-
dentalomas not responsible for ectopic ACTH secretion,
and leading to a misdiagnosis [33]. Steps necessary for
the etiological diagnosis of ACTH dependent Cusging’s











Figure 2 Steps necessary for the etiological diagnosis of ACTH-depenDifferential diagnosis
– Chronic exogenous administration of
glucocorticoids
– Pseudo-Cushing states as described previously
– ACTH dependent Cushing’s syndrome: Ectopic
ACTH secretion (see above)
– ACTH independent Cushing’s syndrome will be
ruled out by inappropriately normal or increased
ACTH levels.
– Functional hypercortisolism during pregnancy
Clinical management
Transsphenoidal surgery is the first line treatment of
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dent Cushing’s syndrome.
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depending on local invasion and the experience of the
neurosurgeon[43-45]. Remission should be defined by
normal ACTH and cortisol circadian rhythms, and
suppressed cortisol value after overnight/low dose dexa-
methasone suppression test.
The appropriateness of surgery in the lack of visua-
lized pituitary adenoma remains a matter of debate [46].
When extensive samplings and dynamic tests confirm
that hypercortisolism is due to Cushing’s disease, and pi-
tuitary MRI seems normal, literature data report a range
of surgical efficacy varying from less than 50 to 70% of
remission, often associated with induced hypopituitarism
and/or diabetes insipidus. The risk of late recurrence
after presumably curative surgery is estimated to be
close to 25% [47]. Several criteria have been reported as
predictive factors for long-term remission: low immedi-
ate post-surgical early morning cortisol/ACTH levels,
cortisol suppression after 1 mg overnight dexametha-
sone suppression test, lack of cortisol/ACTH response
to desmopressin or coupled dexamethasone desmopres-
sin test [48-51]. However, it is still difficult to predict
which patients are at greater risk of recurrence, as some
patients uncured immediately after surgery, might how-
ever present delayed remission [52]. As a consequence,
and due to the high risk of recurrence, it seems difficult
to talk about “cure” in patients with surgically treated
Cushing’s disease; the term “remission” seems more ap-
propriate. In other words, even long-term remission
after surgery should lead to at least a prolonged clinical
close follow-up.
In case of immediate surgical failure or late recur-
rence, several therapeutic modalities are available: sec-
ond pituitary surgery, medical treatments, radiation
techniques, or bilateral adrenalectomy[53]. Only some
of these treatments (surgery, and radiation techniques
after à prolonged period) can lead to long-term
remission.
Second surgery
Several teams reported the benefits of a second surgical
procedure, either in the first days following initial
surgery, or later. A recent study reported a possibility of
delayed remission after initial surgery in about 5% of
cases. This should be in favor of a delayed rather than
an immediate approach. Efficacy is usually observed in
50-70% of cases, frequently associated with an increased
risk of hypopituitarism, diabetes insipidus, and cerebro-
spinal fluid leak [54,55].
Medical treatments
Medical treatments aim at decreasing synthesis and
secretion of cortisol, blocking glucocorticoid recep-
tors, or inhibiting ACTH secretion. The maindrawback of these drugs is that they are only suspen-
sive, i.e. hypercortisolism may be controlled but still
uncured, requiring a long-term period of treatment.
There are 4 main indications of medical treatment: in
case of contra-indication or refusal of surgery, in the
lack of adenoma image on pituitary MRI, waiting for
radiation techniques to be effective, as a multimodality
approach in the rare cases of pituitary carcinomas.
Steroidogenesis inhibitors
 Op’DDD (mitotane, LysodrenW) is derived from
insecticide dichloro-diphenyl- dichloroethane
(DDD). Op’DDD inhibits side chain cleavage of
cholesterol and also other cytochrome P450
enzymes (11-alpha and 18-hydroxylase) and non-
P450 enzyme (3 beta-hydroxysteroiddeshydrogenase).
In Cushing’s disease, it is used as an inhibitor of
cortisol secretion.Op’DDD is usually effective in more
than 50% cases, and frequently induces adrenal
atrophy; however, gastro-intestinal tolerance is usually
bad, and there is a 4-week delay to obtain maximal
efficacy due to its accumulation in adipose tissue.
There is a narrow difference between efficacy and
toxicity levels. Main side effects are digestive (nausea,
vomiting, diarrhea), neurologic (sleepiness, asthenia)
and metabolic (hypercholesterolemia). Mitotane
modifies metabolic clearance of steroids with
consequent gynecomastia in men and alteration of
contraceptive effects of pills [56,57]. Pregnancy is
forbidden during mitotane therapy and for two years
after drug withdrawal due to teratogenic effects
[41,58,59].
 Ketoconazole is an antifungal agent with
steroidogenesis inhibitor effects linked to inhibition
of cytochrome P450 enzymes. It was reported to
normalize cortisol levels in Cushing’s disease in
about 50% of cases. Side effects include rare severe
liver injury (1/15000 cases), and gastro-intestinal
intolerance [60].
 Metyrapone (MétopironeW) is a pyridine derivative
that blocks cortisol synthesis by mainly inhibition of
11 beta hydroxylase. Metyrapone is rapidly effective
in about 50% of hypercortisolic states: it usually
induced low blood potassium levels, and
hyperandrogenism [61].
 Etomidate (HypnomidateW) is an intravenous
anaesthetic agent. It inhibits cortisol synthesis by
inhibiting CYP11B1 with 11-beta hydroxylase
activity, and cytochrome P450scc at high
concentrations. Etomidate is a very potent
anticortisolic drug, limited by the fact that it can
only be used intravenously: it should thus be
reserved for severe hypercortisolic states [62].
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Mifepristone is currently the only available glucocorticoid
receptor antagonist. Only rare cases have been reported to
date. The drug seems to be highly effective in controlling
clinical signs of hypercortisolism. However, due to its
mode of action, there is a high risk of hypokalemia, and
there is no biological means to monitor the patient. Treat-
ment dose adjustment is thus only based on subjective
signs [63].
ACTH-lowering agents
Cabergoline is a dopamine agonist well known for its
anti-secretory and anti-tumoral efficacy in prolactinomas.
Corticotroph adenomas can express dopamine receptors.
Recent studies reported that about 25% of patients treated
by high doses of carbergoline for CD could be controlled
as well [64-66]. A strict echocardiographic follow-up is
required, due to a dose-dependent risk of valvulopathy.
Pasireotide is a somatostatin agonist with a particular
binding affinity for somatostatin receptor (sstr) isoforms
1, 2, 3 and 5. This specific affinity for sstr5 could be of
major interest in CD. Clinical trials are ongoing to deter-
mine efficiency of this drug. Preliminary results suggest
that pasireotide is able to decrease cortisol levels in the
majority of patients, but only few reach normalized
values. There is a risk of induction or worsening of
hyperglycemia in 1/3 cases [67-69].
Radiation techniques
Radiation techniques have been widely used as a treat-
ment of Cushing’s disease. Different techniques are avail-
able, mainly based on fractionated radiotherapy or
stereotactic radiosurgery. Radiotherapy induces remis-
sion in the majority of cases, but also panhypopituitar-
ism in more than 80% of patients [70]. Due to the slow
decrease of ACTH levels, delay to remission can vary
from 2–3 to 10 years, depending on initial hormone
levels. Stereotactic radiosurgery is delivered in a single
session. It is theoretically a more precise technique, lead-
ing to a lower risk of hypopituitarism. However, the rate
of remission is lower, reported in only 50% of cases.
Radiosurgery should thus be reserved for small and low
secreting lesions [71]. For both techniques, medical
treatments need to be given between the procedure and
maximal efficacy, i.e. for 2–5 years, to control cortisol
hypersecretion waiting for normalization.
Bilateral adrenalectomy
It can be used either in case of failure of pituitary sur-
gery, or when hypercortisolism is severe, requiring a
rapidly active treatment. Bilateral adrenalectomy
resolves cortisol hypersecretion in the vast majority of
cases, with a low risk of perioperative complications
[72]. One might consider trying to decrease the level ofhypersecretion by antisecretory therapy for a short
period of time before bilateral adrenalectomy, but this
specific point has never been really evaluated. The
major and expected side effect of bilateral adrenalect-
omy is adrenal insufficiency. Another possible adverse
effects is Nelson’s syndrome, which is a pituitary tumor
progression observed after adrenalectomy [73].
Temozolomide
In rare cases, CD can be induced by aggressive pituitary
tumors, and still more rarely by pituitary carcinomas.
Due to frequent recurrences, they usually require repeat
surgery, and aggressive treatments. The rarity of cases
makes it difficult to define a consensual therapeutic
approach. Recent studies pointed out the benefits of
temozolomide, but prospective long-term studies will be
necessary to ascertain this point [74-76].
Prognosis
The risks of chronic hypercortisolic state include excess
morbidity and mortality due to increased cardio-vascular
risk factors (hypertension, dyslipidemia, diabetes melli-
tus, metabolic syndrome) leading to heart defect. More-
over, hypercortisolism is responsible for coagulopathy
[77] and atherosclerosis [78], which also increase the risk
to develop cardiovascular diseases. Recent data suggest
that part of these defects due to hypercortisolism might
remain after remission [78] even if the mortality rate
would go back to normal [79]. Frequency of infectious
diseases is also increased, as well as delayed healing.
Hypercortisolism can induce severe osteoporosis in
about 30% cases, and osteopenia in half of them. Also,
acute cortisol excess can induce severe hypokalemia, as
well as elevated blood pressure levels, and sometimes
psychiatric signs [26,80]. Finally, more than half of
patients with CS can present with psychiatric signs, from
mild to severe depression, and cognitive dysfunction
[81].
Future prospects
Future research should focus on
1. The pathophysiological mechanisms leading to
corticotroph adenomas. Only rare data are available
on the early events leading to pituitary adenomas in
general, and corticotroph adenomas in particular.
2. The way to improve sensitivity/specificity of
diagnostic methods for subclinical Cushing’s
syndrome. Some patients are diagnosed with
Cushing’s syndrome several years after a prolonged
treatment for hypertension, osteoporosis. . .
3. The way to diagnose earlier patients with a high risk
of post-surgical recurrence. About 20% of patients
with what is supposedly the best predictive factor of
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surgery) still present long term recurrence of their
disease.
4. The development of safe and effective medical
treatments. Currently available drugs are either
poorly effective and/or have bad tolerance.
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